Brigatinib
Cat.No:IB1190 Solarbio
CAS:1197953-54-0
Storage:Powder:-20℃,2 years
Purity:≥98%
Appearance:White to yellow Solid
Qty:
Size:
{{cart_num}}
My Cart>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
Protein Tyrosine Kinase/PTK >
BrigatinibCAS:1197953-54-0
Storage:Powder:-20℃,2 years
Purity:≥98%
Appearance:White to yellow Solid
Qty:
Size:
CAS | 1197953-54-0 |
Name | Brigatinib |
Molecular Formula | C29H39ClN7O2P |
Molecular Weight | 584.09 |
Solubility | Soluble in DMSO ≥0.1mg/mL |
Purity | ≥98% |
Appearance | White to yellow Solid |
Storage | Powder:-20℃,2 years |
EC | EINECS 1592732-453-0 |
MDL | MFCD29472221 |
SMILES | CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3)NC4=NC=C(C(=N4)NC5=CC=CC=C5P(=O)(C)C)Cl)OC |
InChIKey | AILRADAXUVEEIR-UHFFFAOYSA-N |
InChI | InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34) |
PubChem CID | 68165256 |
Target Point | ALK;EGFR;FLT3;IGF-1R;ROS1 |
Passage | Angiogenesis; Protein Tyrosine Kinase/RTK |
Background | It is a potent and selective ALK inhibitor. |
Biological Activity | Brigatinib 是有效,选择性的 ALK 抑制剂,IC50 值为 0.6 nM。[1-3] |
IC50 | 0.6nM(ALK)[1] |
In Vitro | Brigatinib有效抑制ALK的体外激酶活性(IC50,0.6 nM)和测试的所有五种突变体变体,包括G1202R(IC50,0.6-6.6 nM)。 Brigatinib表现出高度的选择性,仅抑制11种额外的天然或突变激酶,IC50 1000nM)。在细胞试验中,brigatinib分别抑制ALK和ROS1,IC50分别为14和18 nM。 Brigatinib以低约11倍的效力(IC50,148-158nM)抑制FLT3和IGF-1R,并抑制FLT3和EGFR的突变体变异,效力低15-35倍(IC50,211-489nM)。 Brigatinib在三种ALK阴性ALCL和NSCLC细胞系中抑制细胞生长,GI50值范围为503至2,387 nM [1]。 Brigatinib抑制ALK活性并消除ALK成瘾神经母细胞瘤细胞系的增殖,IC50为75.27±8.89 nM。 Brigatinib分别以10和4 nM水平抑制ALK-I1171N和ALK-G1269A突变受体[3]。 |
In Vivo | Brigatinib(10,25或50mg / kg每日一次,po)导致ALK + Karpas-299(ALCL)和H2228(NSCLC)异种移植小鼠模型中肿瘤生长的剂量依赖性抑制。与克唑替尼相比,Brigatinib显著增强携带ALK +脑肿瘤的小鼠的存活[1]。 Brigatinib(10,25,50 mg / kg,po)导致剂量依赖性抗肿瘤活性,在NSCLC小鼠模型中具有肿瘤消退[2]。 |
Cell Experiment | 以每孔15,000个细胞接种细胞,连续稀释所示抑制剂。 72小时后,通过刃天青评估细胞活力。通过将数据拟合至log(抑制剂浓度)与标准化响应(可变斜率)方程,用GraphPad Prism 6.0计算IC 50值。每个实验一式两份进行并重复至少三次。 |
Animal Experiment | 小鼠:(1)8至10周龄雌性SCID /米色小鼠静脉注射每只小鼠5×106个H3122细胞,当平均肿瘤大小达到300mm3时,随机选择治疗组(n = 10)(零日)。治疗以10mL / kg剂量体积口服给药连续21天。每周测量皮下肿瘤两次或三次。使用公式(L×W2)/ 2计算肿瘤体积(以mm 3计)。当肿瘤达到宿主体重的10%时,通过CO 2窒息使动物安乐死。(2)8至10周龄雌性SCID /米色小鼠皮下注射每只小鼠2.5×106个Karpas-299细胞,当平均肿瘤大小达到约180mm3时,随机选择治疗组(n = 10)(第零天)。以10mL / kg剂量体积连续14天口服给药。如针对H3122模型所述测量和计算肿瘤体积。 |
Kinase Experiment | 进行289种激酶的体外HotSpotSM激酶谱分析。该测定在10μM[33P] -ATP存在下进行,使用浓度范围为0.05nM至1μM的布立替尼。 |
Data Literature Source | [1]. Zhang S,et al. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. Clin Cancer Res. 2016 Nov 15;22(22):5527-5538 [2]. Huang WS,et al. Discovery of Brigatinib (AP26113),a Phosphine Oxide-Containing,Potent,Orally Active Inhibitor of Anaplastic Lymphoma Kinase. J Med Chem. 2016 May 26;59(10):4948-64. [3]. Siaw JT,et al. Brigatinib,an anaplastic lymphoma kinase inhibitor,abrogates activity and growth in ALK-positive neuroblastoma cells,Drosophila and mice. Oncotarget. 2016 May 17;7(20):29011-22 |
Unit | Bottle |
Specification | 5mg 10mg 50mg 100mg |
是一种有效的、选择性的ALK抑制剂。
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.